Revelation Biosciences Inc REVB
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-10-08 |
| Shares Out. | 3,910,000 |
| Website | revbiosciences.com/ ↗ |
| Phone | 13026457400 |
| Employees | 9 |
| Net Income | -$3.0M |
| Free Cash Flow | -$8.8M |
| Total Assets | $15.0M |
| Total Liabilities | $2.1M |
| Equity | $13.0M |
About Revelation Biosciences Inc
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.
Revelation Biosciences Inc is a publicly traded company under the ticker symbol REVB on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2026-07-01)